SG11201912881SA - Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide - Google Patents
Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideInfo
- Publication number
- SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912881SA true SG11201912881SA (en) | 2020-01-30 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912881SA SG11201912881SA (en) | 2017-07-05 | 2018-07-04 | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (enExample) |
| EP (1) | EP3649117B1 (enExample) |
| JP (2) | JP2020525475A (enExample) |
| KR (1) | KR102645911B1 (enExample) |
| CN (1) | CN110831932A (enExample) |
| AU (1) | AU2018296423B2 (enExample) |
| BR (1) | BR112020000099A2 (enExample) |
| CA (1) | CA3067489A1 (enExample) |
| CL (1) | CL2020000002A1 (enExample) |
| EA (1) | EA202090193A1 (enExample) |
| IL (1) | IL271764B2 (enExample) |
| MA (1) | MA50972A (enExample) |
| MY (1) | MY206357A (enExample) |
| PH (1) | PH12020500040A1 (enExample) |
| SG (1) | SG11201912881SA (enExample) |
| UA (1) | UA126582C2 (enExample) |
| WO (1) | WO2019008034A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3554490T (lt) | 2016-12-16 | 2022-04-25 | Idorsia Pharmaceuticals Ltd | Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių |
| CA3050348A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| UA126582C2 (uk) * | 2017-07-05 | 2022-11-02 | Ідорсія Фармасьютікалз Лтд | Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду |
| EP4076405A1 (en) | 2019-12-20 | 2022-10-26 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| KR20240046879A (ko) * | 2021-08-17 | 2024-04-11 | 한국과학기술원 | Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40281B1 (fr) * | 2014-06-03 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
| WO2016041892A1 (en) | 2014-09-15 | 2016-03-24 | Actelion Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
| LT3554490T (lt) | 2016-12-16 | 2022-04-25 | Idorsia Pharmaceuticals Ltd | Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių |
| CA3050348A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| UA126582C2 (uk) * | 2017-07-05 | 2022-11-02 | Ідорсія Фармасьютікалз Лтд | Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду |
-
2018
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3649117B1 (en) | 2024-10-09 |
| US11059803B2 (en) | 2021-07-13 |
| EP3649117A1 (en) | 2020-05-13 |
| UA126582C2 (uk) | 2022-11-02 |
| US20210300894A1 (en) | 2021-09-30 |
| KR20200018698A (ko) | 2020-02-19 |
| PH12020500040A1 (en) | 2020-10-12 |
| WO2019008034A1 (en) | 2019-01-10 |
| EA202090193A1 (ru) | 2020-06-03 |
| US11555025B2 (en) | 2023-01-17 |
| AU2018296423B2 (en) | 2022-07-28 |
| JP2020525475A (ja) | 2020-08-27 |
| MA50972A (fr) | 2020-10-14 |
| CA3067489A1 (en) | 2019-01-10 |
| MY206357A (en) | 2024-12-12 |
| IL271764A (en) | 2020-02-27 |
| CL2020000002A1 (es) | 2020-07-31 |
| KR102645911B1 (ko) | 2024-03-08 |
| JP2023123679A (ja) | 2023-09-05 |
| CN110831932A (zh) | 2020-02-21 |
| AU2018296423A1 (en) | 2020-02-20 |
| IL271764B1 (en) | 2023-06-01 |
| IL271764B2 (en) | 2023-10-01 |
| BR112020000099A2 (pt) | 2020-07-07 |
| US20200165221A1 (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271764A (en) | Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| IL274488A (en) | Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| GB201609607D0 (en) | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts | |
| IL275292A (en) | Inhibitors of the integrated stress response pathway | |
| IL257390B (en) | Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors | |
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| IL285675A (en) | Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| LT3448849T (lt) | Indazolo sintezė | |
| IL276977A (en) | Creation of piezoelectric devices | |
| SG11202011014VA (en) | Inhibitors of integrated stress response pathway | |
| GB201609603D0 (en) | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide | |
| IL266003A (en) | Salts of indazole derivatives and their crystals | |
| PL3099302T3 (pl) | Formy krystaliczne 2-(tert-butyloamino)-4-((1r,3r,4r)-3-hydroksy-4-metylocykloheksyloamino) -pirymidyno-5-karboksyamidu | |
| ZA201907022B (en) | Reduction of regenerator clogging | |
| ZA202003028B (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
| HK40025427A (en) | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| SG11202103847QA (en) | Estimation of asymmetric aberrations | |
| IL261445A (en) | Herbicidal compositions containing 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1h-tetrazole-5-yl)-4-(trifluoromethyl)benzamide | |
| SI3643704T1 (sl) | Novi intermediati za pripravo remifentanil hidroklorida | |
| EP3687987A4 (en) | CRYSTALLINE FORMS OF LENALIDOMIDE | |
| EP3773536A4 (en) | 1,4-SUBSTITUTES OF ISOQUINOLINE USED AS PROTEIN-PROTEIN INTERACTION INHIBITORS BETWEEN KEAP1 / NRF2 | |
| IT201700050223A1 (it) | Procedimento per la preparazione di dexlansoprazolo cristallino | |
| IL249496A0 (en) | Improved process for the preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-h4,2,1-1-triazol-3-yl)benzoyl azide | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| GB201705905D0 (en) | Pack of disposable wipes |